Gold bars to be exempt from tariffs, White House clarifies
After these transactions, Hollman holds 82,139 shares of Janux Therapeutics directly.
After these transactions, Hollman holds 82,139 shares of Janux Therapeutics directly.
After these transactions, Hollman holds 82,139 shares of Janux Therapeutics directly.
In other recent news, Janux Therapeutics has been the focus of several analyst updates following promising clinical results for its leading drug candidate, JANX007. Clear Street initiated coverage on Janux Therapeutics, assigning the biopharmaceutical company a Buy rating and a price target of $80. The firm expressed confidence in JANX007's ability to disrupt the prostate cancer market, which is valued at approximately $5 billion.
Scotiabank (TSX:BNS) adjusted its outlook on Janux Therapeutics, increasing the price target to $62 from the previous $42, while maintaining a Sector Perform rating. The firm's decision came after updated dose-escalation results from an ongoing Phase 1 trial of JANX007, which is being evaluated for the treatment of advanced metastatic castration-resistant prostate cancer (mCRPC).
Jones Trading increased the company's target to $105, reflecting confidence in the future prospects of the company's pipeline and technology platform. TD Cowen reiterated a Buy rating on Janux Therapeutics, highlighting impressive prostate-specific antigen (PSA) reduction rates of the '007 candidate.
Stifel raised its price target for Janux Therapeutics to $115, up from the previous $70, while maintaining a Buy rating. The firm adjusted the probability of success for the second-line and third-line mCRPC treatments to 50% and 65%, respectively, from the initial 35% and 50%.
These recent developments suggest that '007 could become the preferred non-androgen therapy for mCRPC, with the potential to generate multiple billions in revenue. Further updates on '007, as well as on '008, are expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.